Drug
RO5126766 clinical trials
Also written Avutometinib, CH5126766 and RG 7304.
- studies test it
- 26
- open now
- 12
- in phase 3
- 1
- first study started
- 2008
Keep track of what changes. Save the RO5126766 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2023 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 11
- Phase 2
- 18
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 17
Verastem, Inc. (8) · Memorial Sloan Kettering Cancer Center (5) · Emory University (2) · M.D. Anderson Cancer Center (2) · Institute of Cancer Research, United Kingdom (1) · Hoffmann-La Roche (1) · University of Virginia (1) · Girish Dhall, MD (1)
Often tested with
Tested in the same studies.
Defactinib (14) · Sotorasib (1) · Avutometinib and Defactinib (1) · Letrozole (1) · Cetuximab (1) · Everolimus (1) · Abemaciclib (1) · Fulvestrant (1)
Studies
Open first, then newest update. How each study uses RO5126766 is read from its arms, and is right about nine times in ten.
Testing it · 26
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06394804Written as Avutometinib
- A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06007924Written as Avutometinib
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as avutometinib
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT06369259Written as Avutometinib
- Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic AdenocarcinomaNot yet recruitingPhase 1/2University of VirginiaNCT07824960Written as Avutometinib (VS-6766) + Defactinib (VS-6063)
- Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingPhase 2Girish Dhall, MDNCT07743554Written as avutometinib capsule + defactinib tablet
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT07318324Written as Avutometinib
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingPhase 1/2Adrienne G. WaksNCT05608252Written as VS-6766
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaRecruitingPhase 2Washington University School of MedicineNCT07126158Written as Avutometinib
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingPhase 2Emory UniversityNCT06495125Written as Avutometinib
- Avutometinib and Defactinib in Diffuse Gastric CancerRecruitingPhase 2Ryan H. Moy, MD, PhDNCT06487221Written as Avutometinib
- A Phase 2 Study of Avutometinib (VS-6766) Plus DefactinibRecruitingPhase 2University of OklahomaNCT05512208Written as Avutometinib (VS-6766) + defactinib
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05787561Written as Avutometinib (VS-6766)
- Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsCompletedPhase 1/2Verastem, Inc.NCT05375994Written as avutometinib (VS-6766) and adagrasib
- A Study of Avutometinib for People With Solid Tumor CancersActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT06104488Written as Avutometinib
- Phase I Trial of Defactinib and VS-6766.Active, not recruitingPhase 1Institute of Cancer Research, United KingdomNCT03875820Written as VS-6766
- Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingPhase 1/2Verastem, Inc.NCT05074810Written as avutometinib and sotorasib
- A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsActive, not recruitingPhase 2Verastem, Inc.NCT06682572Written as Avutometinib (VS-6766) + Defactinib (VS-6063)
- Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaActive, not recruitingEarly Phase 1Emory UniversityNCT05798507Written as Avutometinib
- Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerActive, not recruitingPhase 1/2Verastem, Inc.NCT05669482Written as avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
See all 26 studies that test RO5126766 →
Given in every arm · 4 — RO5126766 is usual care beside what is tested
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT06630260Written as Avutometinib
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingPhase 1/2University of UtahNCT06194929Written as Avutometinib
- Phase I Trial of VS-6766 Alone and in Combination With EverolimusCompletedPhase 1Royal Marsden NHS Foundation TrustNCT02407509Written as VS-6766
- A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal CancerSuspendedPhase 1/2University of ChicagoNCT05200442Written as VS-6766/avutometinib
Codes
What other systems call RO5126766 · ClinicalTrials.gg INT006219
- MeSH (NLM) C577924RO5126766One source NLM
- UNII (FDA) D0D4252V97AVUTOMETINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C577924 | RO5126766 | One source NLM |
| UNII (FDA) | D0D4252V97 | AVUTOMETINIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.